Molecular classification of hormone receptor-positive /HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies.

ABSTRACT: Significant heterogeneity exists in hormone receptor (HR)-positive/HER2-positive (HR⁺/HER2⁺) breast cancer, contributing to suboptimal pathological complete response rates with conventional neoadjuvant treatment regimens. Overcoming this challenge requires precise molecular classification, which is pivotal for the development of targeted therapies. We conducted molecular typing on a cohort of 211 patients with HR⁺/HER2⁺ breast cancer and performed a comprehensive analysis of the efficacy of various neoadjuvant treatment regimens. Our findings revealed four distinct molecular subtypes, each exhibiting unique characteristics and therapeutic implications. The HER2-enriched subtype, marked by activation of the HER2 signaling and hypoxia-inducible fac

SUBMITTER: Liu C 

PROVIDER: S-EPMC11937365 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature